Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | FAAH | O00519 | 6/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20660561 | 1.00 | OPRK1 (0.59) | OPRK1KMT2AMEN1SMN1; SMN2HSD17B10 | |
| SCHEMBL29122639 | 1.00 | OPRK1 (0.59) | OPRK1KMT2AMEN1SMN1; SMN2HSD17B10 | |
| SCHEMBL20660719 | 1.00 | OPRK1 (0.59) | OPRK1KMT2AMEN1SMN1; SMN2HSD17B10 | |
| SCHEMBL20660653 | 1.00 | OPRK1 (0.59) | OPRK1KMT2AMEN1SMN1; SMN2HSD17B10 | |
| SCHEMBL28398818 | 1.00 | OPRK1 (0.59) | OPRK1KMT2AMEN1SMN1; SMN2HSD17B10 | |
| SCHEMBL10329430 | 0.94 | OPRK1 (0.62) | OPRK1KMT2AMEN1SMN1; SMN2HSD17B10 | |
| SCHEMBL27476119 | 0.88 | OPRK1 (0.66) | OPRK1KMT2AMEN1SMN1; SMN2HSD17B10 | |
| SCHEMBL27268103 | 0.87 | ALDH1A1 (0.60) | OPRK1SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL11284305 | 0.87 | OPRK1 (0.61) | OPRK1KMT2AMEN1SMN1; SMN2HSD17B10 | |
| SCHEMBL14723641 | 0.86 | HDAC1 (0.62) | OPRK1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1988002253-A1 | COATING MEMBRANE AND COMPOSITIONS PREPARED THEREFROM | VALDUCCI ROBERTO (IT) | 1988-04-07 | — | — | WO | claimed |
| CN-118359629-A | Abuse resistant long-acting release oxymorphone prodrug compounds and uses thereof | 苏州润鑫达泰生物医药有限公司 | 2024-07-19 | — | — | CN | disclosed |
| CN-118255776-A | Abuse resistant long-acting release opioid prodrugs | 苏州润鑫达泰生物医药有限公司 | 2024-06-28 | — | — | CN | disclosed |
| CN-111107849-B | Abuse resistant long-acting release opioid prodrugs | 苏州润鑫达泰生物医药有限公司 | 2024-03-29 | — | — | CN | disclosed |
| US-20220356188-A1 | ABUSE-RESISTANT LONG-ACTING RELEASE OPIOID PRODRUGS | SUZHOU RUNXINDATAI PHARMACEUTICS LTD CO. (CN) | 2022-11-10 | — | — | US | disclosed |
| US-11254685-B2 | Abuse-resistant long-acting release opioid prodrugs | SUZHOU RUNXINDATAI PHARMACEUTICS LTD CO. (CN) | 2022-02-22 | — | — | US | disclosed |
| EP-3654977-A1 | ABUSE-RESISTANT LONG-ACTING RELEASE OPIOID PRODRUGS | Suzhou Runxindatai Pharmaceutics Ltd Co. (CN) | 2020-05-27 | — | — | EP | disclosed |
| US-20200148694-A1 | ABUSE-RESISTANT LONG-ACTING RELEASE OPIOID PRODRUGS | SUZHOU RUNXINDATAI PHARMACEUTICS LTD CO. (CN) | 2020-05-14 | — | — | US | disclosed |
| CN-111107849-A | Abuse resistant extended release opioid prodrugs | 苏州润鑫达泰生物医药有限公司 | 2020-05-05 | — | — | CN | disclosed |
| WO-2019018638-A1 | ABUSE-RESISTANT LONG-ACTING RELEASE OPIOID PRODRUGS | SUZHOU RUNXINDATAI PHARMACEUTICS LTD CO. (CN) | 2019-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220356188-A1 | ABUSE-RESISTANT LONG-ACTING RELEASE OPIOID PRODRUGS | OPRK1, OPRM1, OPRL1 | OPRK1 1/4885KMT2A 2848/4885MEN1 4834/4885 |
| US-11254685-B2 | Abuse-resistant long-acting release opioid prodrugs | OPRK1, OPRM1, OPRL1 | OPRK1 1/4885KMT2A 2848/4885MEN1 4834/4885 |
| US-20200148694-A1 | ABUSE-RESISTANT LONG-ACTING RELEASE OPIOID PRODRUGS | OPRK1, OPRM1, OPRL1 | OPRK1 1/4885KMT2A 2848/4885MEN1 4834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.